UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Net income	$ 7,414	$ 6,014	$ 6,258
Depreciation	707	563	555
Amortization	2,066	44	34
Gain on investments	(6)	(38)	(212)
Provision for (recovery of) losses on accounts receivable	77	6	7
Loss on disposal of assets		0	1
Deferred income taxes	(549)		230
Stock-based compensation expense	95	83	98
Accounts receivable	502	110	290
Accrued interest and other receivables	(31)	(165)	69
Inventories	(624)	286	(83)
Prepaid expenses and other current assets	529	58	(10)
Accounts payable	(1,213)	52	(73)
Accrued expenses	2,158	143	63
Deferred revenue	(66)
Other liability	307
Net cash provided by operating activities	11,365	7,157	7,226
Capital expenditures for property and equipment	(247)	(1,532)	(466)
Capital expenditures for intangible assets	(10)	(2)	(8)
Purchases of investments	(500)	(1,600)	(3,800)
Proceeds from sale of investments	15,155	5,839	1,116
Net cash paid in acquisition	(41,084)
Net cash provided by (used in) investing activities	(26,685)	2,705	(3,158)
Proceeds from issuance of common stock - options	485	425	132
Common stock purchased and retired		(439)	(116)
Tax benefit attributable to exercise of stock options	34	38	14
Proceeds from notes payable	26,934
Repayments of note payable	(5,942)	(413)	(463)
Dividends paid	(3,433)	(6,030)	(3,337)
Net cash provided by (used in) financing activities	18,078	(6,419)	(3,770)
Effect of exchange rate changes on cash	(41)	(35)	15
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	2,717	3,408	313
CASH AT BEGINNING OF PERIOD	3,818	410	97
CASH AT END OF PERIOD	6,534	3,818	410
Cash paid during the period for income taxes	2,685	2,810	3,075
Cash paid during the period for interest	$ 859	$ 25	$ 51